Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
POM+ DEX · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 4 mg Oral POM + 40 mg Oral DEX | EXPERIMENTAL | Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle |
| 2 mg Oral POM + 40 mg Oral DEX | EXPERIMENTAL | Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle |
| Name | Type | Description |
|---|---|---|
| 4 mg Oral POM + 40 mg Oral DEX | DRUG | - |
| 2 mg Oral POM + 40 mg Oral DEX | DRUG | - |
Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: 1. Must be ≥ 18 years at the time of signing the informed consent form 2. Must understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures 3. Must be abl...
Top 20 of 25 competitors
POM+ DEX is a combination of pomalidomide and dexamethasone being studied for use in patients with Multiple Myeloma, specifically those with impaired renal function. It is an investigational small molecule therapy in Phase 1 clinical development, and it is not yet approved by the FDA.
POM+ DEX is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research to evaluate the pharmacokinetics and safety of this combination therapy in patients with Multiple Myeloma and renal impairment.
POM+ DEX is in Phase 1 clinical development. A Phase 1 study has been completed, which evaluated the pharmacokinetics and safety of pomalidomide in patients with Multiple Myeloma and impaired renal function. The drug remains investigational and is not FDA approved.
POM+ DEX has one completed clinical trial, NCT01575925, titled "Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)." This Phase 1 study enrolled 25 participants in the United States and Canada.
POM+ DEX refers to the combination of pomalidomide and dexamethasone. The clinical trial NCT01575925 evaluates pomalidomide in patients with Multiple Myeloma and renal impairment, with dexamethasone as part of the treatment regimen. This combination is being studied for its safety and pharmacokinetics.